Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

Researchers shared findings today at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. San ...

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...

By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...

A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...

A Dexcom continuous glucose monitor (CGM) helped adults with type 2 diabetes not using insulin improve blood sugar control in ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted clearance to a next-generation ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...

It’s here: Dexcom is kicking off the international rollout of the newest generation of its real-time continuous glucose monitor, the G7, to help adults and children with diabetes digitally track their ...

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) ...